TPN-101 ( DrugBank: - )

3 diseases

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	3
127	Frontotemporal lobar degeneration	3
325	Hereditary autoinflammatory syndrome	1

2. Amyotrophic lateral sclerosis

Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-002251-11-ES (EUCTR)	31/01/2022	08/10/2021	A clinical study to learn whether a new drug, TPN-101, is safe when given to patients with amyotroph ...	A Phase 2a Study of TPN-101in Patients with C9ORF72 ALS/FTD (Amyotrophic Lateral Sclerosis and/or Fr ...	Amyotrophic lateral sclerosis or frontotemporal dementia due to a genetic mutation called C9orf72 he ...	Product Name: TPN-101 Product Code: TPN-101 INN or Proposed INN: CENSAVUDINE	Transposon Therapeutics, Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	France;United States;Canada;Belgium;Spain;Netherlands;Germany;United Kingdom
2	EUCTR2021-002251-11-DE (EUCTR)	06/12/2021	02/08/2021	A clinical study to learn whether a new drug, TPN-101, is safe when given to patients with amyotroph ...	A Phase 2a Study of TPN-101in Patients with C9ORF72 ALS/FTD (Amyotrophic Lateral Sclerosis and/or Fr ...	Amyotrophic lateral sclerosis or frontotemporal dementia due to a genetic mutation called C9orf72 he ...	Product Name: TPN-101 Product Code: TPN-101 INN or Proposed INN: CENSAVUDINE	Transposon Therapeutics, Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	France;United States;Canada;Spain;Belgium;Netherlands;Germany;United Kingdom
3	NCT04993755 (ClinicalTrials.gov)	October 1, 2021	19/7/2021	A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD	A Phase 2a Study of TPN-101in Patients With Amyotrophic Lateral Sclerosis (ALS) and/or Frontotempora ...	Amyotrophic Lateral Sclerosis;Frontotemporal Dementia	Drug: TPN-101, 400 mg/day;Drug: Placebo	Transposon Therapeutics, Inc.	NULL	Active, not recruiting	18 Years	N/A	All	42	Phase 2	United States;Belgium;France;Germany;Spain;Netherlands

First Previous1Next Last

127. Frontotemporal lobar degeneration

Clinical trials : 90 / Drugs : 87 - (DrugBank : 30) / Drug target genes : 39 - Drug target pathways : 88

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-002251-11-ES (EUCTR)	31/01/2022	08/10/2021	A clinical study to learn whether a new drug, TPN-101, is safe when given to patients with amyotroph ...	A Phase 2a Study of TPN-101in Patients with C9ORF72 ALS/FTD (Amyotrophic Lateral Sclerosis and/or Fr ...	Amyotrophic lateral sclerosis or frontotemporal dementia due to a genetic mutation called C9orf72 he ...	Product Name: TPN-101 Product Code: TPN-101 INN or Proposed INN: CENSAVUDINE	Transposon Therapeutics, Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	France;United States;Canada;Belgium;Spain;Netherlands;Germany;United Kingdom
2	EUCTR2021-002251-11-DE (EUCTR)	06/12/2021	02/08/2021	A clinical study to learn whether a new drug, TPN-101, is safe when given to patients with amyotroph ...	A Phase 2a Study of TPN-101in Patients with C9ORF72 ALS/FTD (Amyotrophic Lateral Sclerosis and/or Fr ...	Amyotrophic lateral sclerosis or frontotemporal dementia due to a genetic mutation called C9orf72 he ...	Product Name: TPN-101 Product Code: TPN-101 INN or Proposed INN: CENSAVUDINE	Transposon Therapeutics, Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	France;United States;Canada;Spain;Belgium;Netherlands;Germany;United Kingdom
3	NCT04993755 (ClinicalTrials.gov)	October 1, 2021	19/7/2021	A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD	A Phase 2a Study of TPN-101in Patients With Amyotrophic Lateral Sclerosis (ALS) and/or Frontotempora ...	Amyotrophic Lateral Sclerosis;Frontotemporal Dementia	Drug: TPN-101, 400 mg/day;Drug: Placebo	Transposon Therapeutics, Inc.	NULL	Active, not recruiting	18 Years	N/A	All	42	Phase 2	United States;Belgium;France;Germany;Spain;Netherlands

First Previous1Next Last

325. Hereditary autoinflammatory syndrome

Clinical trials : 5 / Drugs : 11 - (DrugBank : 6) / Drug target genes : 2 - Drug target pathways : 35

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05613868 (ClinicalTrials.gov)	March 2023	7/11/2022	TPN-101 in Aicardi-Goutières Syndrome (AGS)	A Phase 2a Study of TPN-101 in Patients With Aicardi-Goutières Syndrome (AGS)	Aicardi-Goutières Syndrome (AGS)	Drug: TPN-101	Transposon Therapeutics, Inc.	NULL	Not yet recruiting	12 Months	N/A	All	16	Phase 2	France;Italy;United Kingdom

First Previous1Next Last